More Alzheimer's drugs head for FDA review: what scientists are watching

Eli Lilly and other pharma firms have begun submitting their anti-amyloid drug hopefuls for approval. But questions linger over the controversial precedent set by Biogen's aducanumab. Eli Lilly and other pharma firms have begun submitting their anti-amyloid drug hopefuls for approval. But questions linger over the controversial precedent set by Biogen's aducanumab.
Author(s): Asher Mullard Author Affiliations: More Alzheimer's drugs head for FDA review: what scientists are watching A clinical-trial participant receives an infusion of Biogen's aducanumab in May 2021. Credit: Kayana [...]